Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

LadsAndGents Apr. 2 at 6:37 PM

$VNRX gladly added and now with about 50K shares $SPY

0 · Reply

Samuelstark Apr. 2 at 5:15 PM

$VNRX Still maintaining “buy”

1 · Reply

Samuelstark Apr. 2 at 4:33 PM

$VNRX Agreed. Set it and forget it. It’s a gamble, but after that call it’s one I’m willing to make.

0 · Reply

SuellenD Apr. 2 at 4:30 PM

$VNRX are activity seeking a partnership or maybe buy out. Company isn't spending money on research anymore only looking to market. There are several companies looking at them. This isn't a stock to day trade it's one you can buy cheap for long term profit.

1 · Reply

OpendoorLambo Apr. 2 at 2:23 PM

$VNRX when 0?

0 · Reply

FreePoorR Apr. 2 at 2:20 PM

$VNRX zero today???? If news come again.. will hot zero

0 · Reply

saaria Apr. 2 at 3:42 AM

$VNRX congratulations guys you got scammed

0 · Reply

saaria Apr. 2 at 2:43 AM

$VNRX 10% down overnight

0 · Reply

Kaynoshi Apr. 1 at 8:12 PM

$VNRX it’s called reverse psychology 😒

0 · Reply

2021er Apr. 1 at 7:09 PM

$VNRX $NFLX

0 · Reply

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Mar 31, 2026, 8:16 AM EDT - 5 days ago

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Mar 30, 2026, 8:13 AM EDT - 6 days ago

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Mar 26, 2026, 8:17 AM EDT - 10 days ago

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Mar 25, 2026, 4:12 PM EDT - 10 days ago

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

Mar 25, 2026, 8:17 AM EDT - 11 days ago

Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 18, 2026, 8:17 AM EDT - 18 days ago

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Mar 6, 2026, 8:10 AM EST - 4 weeks ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Feb 25, 2026, 8:10 AM EST - 5 weeks ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 10, 2026, 8:07 AM EST - 7 weeks ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Feb 9, 2026, 5:20 PM EST - 7 weeks ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 4, 2026, 8:45 AM EST - 2 months ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

Jan 30, 2026, 8:50 AM EST - 2 months ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 2 months ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Jan 20, 2026, 8:25 AM EST - 2 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 2 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 3 months ago

VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 8:45 AM EST - 3 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Dec 17, 2025, 8:45 AM EST - 3 months ago

Volition Issues Business Review 2025

Dec 11, 2025, 9:00 AM EST - 4 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 4 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 4 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

Nov 25, 2025, 8:45 AM EST - 4 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Nov 13, 2025, 4:10 PM EST - 5 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 5 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 10, 2025, 8:30 AM EDT - 6 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 6 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 2, 2025, 8:45 AM EDT - 6 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 6 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 7 months ago

Volition Signs First Human Out Licensing Deal

Aug 14, 2025, 4:10 PM EDT - 8 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 8 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 8 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 9 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 9 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 10 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 10 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 11 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 15, 2025, 5:37 PM EDT - 11 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 11 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 11 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Mar 31, 2025, 4:05 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 1 year ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

LadsAndGents Apr. 2 at 6:37 PM

$VNRX gladly added and now with about 50K shares $SPY

0 · Reply

Samuelstark Apr. 2 at 5:15 PM

$VNRX Still maintaining “buy”

1 · Reply

Samuelstark Apr. 2 at 4:33 PM

$VNRX Agreed. Set it and forget it. It’s a gamble, but after that call it’s one I’m willing to make.

0 · Reply

SuellenD Apr. 2 at 4:30 PM

1 · Reply

OpendoorLambo Apr. 2 at 2:23 PM

$VNRX when 0?

0 · Reply

FreePoorR Apr. 2 at 2:20 PM

$VNRX zero today???? If news come again.. will hot zero

0 · Reply

saaria Apr. 2 at 3:42 AM

$VNRX congratulations guys you got scammed

0 · Reply

saaria Apr. 2 at 2:43 AM

$VNRX 10% down overnight

0 · Reply

Kaynoshi Apr. 1 at 8:12 PM

$VNRX it’s called reverse psychology 😒

0 · Reply

2021er Apr. 1 at 7:09 PM

$VNRX $NFLX

0 · Reply

2021er Apr. 1 at 6:07 PM

$VNRX you believe or not. No in between. Pennyflippers will get hurt. I'll hold till the story got told. Theres a chance this small company can can suceed. If they do it will pay out. Statisticly they will fail. Its a bet..

0 · Reply

MonteDSaga Apr. 1 at 6:03 PM

$VNRX stretching for the big run

0 · Reply

MonteDSaga Apr. 1 at 5:13 PM

$VNRX Extension news on the way

1 · Reply

MonteDSaga Apr. 1 at 5:07 PM

$VNRX Munch time.

0 · Reply

frchmn Apr. 1 at 5:05 PM

$VNRX

0 · Reply

Kaynoshi Apr. 1 at 5:01 PM

$VNRX why the f was everyone saying RS vote was yesterday? Bunch of lying cuks here

2 · Reply

MonteDSaga Apr. 1 at 4:31 PM

$VNRX

0 · Reply

Samuelstark Apr. 1 at 4:03 PM

$VNRX Loading up

0 · Reply

saaria Apr. 1 at 2:21 PM

$VNRX sell this shit before delisting

0 · Reply

Kaynoshi Apr. 1 at 2:05 PM

$VNRX any mention of RS on the call?

2 · Reply

saaria Apr. 1 at 1:50 PM

$VNRX Yess another 1% squeez

0 · Reply

saaria Apr. 1 at 1:50 PM

$VNRX news and dump as usual😂😂

0 · Reply

Market Cap	27.18M
Revenue (ttm)	1.23M
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,192.68%
Debt to Equity Ratio	-0.22

Volume	6,937,600
Avg Vol	13,028,352
Day's Range	N/A - N/A
Shares Out	158.48M
Stochastic %K	2%
Beta	1.33
Analysts	Strong Sell
Price Target	$2.06